[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Janssen Research & Development, LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":539},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,79,0,25,[9,42,68,90,111,132,156,176,201,222,243,263,282,302,322,342,363,382,402,423,442,462,482,501,519],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634559","a-real-world-study-of-guselkumab-in-ulcerative-colitis-and-crohns-disease-in-saudi-arabia-100634559",false,"NCT07541261","A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia","A Multi-Center, Non-Interventional Study on Effectiveness and Treatment Persistence of Guselkumab in Patients With ULcerative Colitis and Crohn's DiseasE in Real-World Practice in Saudi Arabia","EAGLE","Inclusion Criteria:\n\n* The participant must be eligible for biologic treatment and initiate guselkumab according to the approved indications described in the current version of the summary of product characteristics (SmPC) approved in Saudi Arabia. The decision to prescribe must solely be made by the treating physician. Enrollment must take place before or at the day of first administration of guselkumab (but after treatment decision by physician) and after obtaining patient consent\n* The participant must have a confirmed diagnosis of moderate-to-severe CD or UC recorded in their medical records\n* The participant must sign a participation agreement\u002Finformed consent form (ICF) allowing source data verification\n\nExclusion criteria:\n\n* Contraindicated to guselkumab per the label\n* Is currently enrolled in an interventional clinical study\n* Has been previously exposed to Interleukin (IL)-23 inhibitors, including tremfya (guselkumab), skyrizi (risankizumab) and omvoh (mirikizumab). As an exception, participants with history of ustekinumab exposure may be included\n* History of more than 4 lines of advanced inflammatory bowel disease (IBD) therapy (biologics and\u002For small molecules)\n* Is unable to provide informed consent","ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","OBSERVATIONAL","The main purpose of this study is to evaluate treatment persistence of guselkumab (that is how long a person keeps taking their prescribed medicine or continues with their treatment plan without stopping) in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.",[26,27,28],"Colitis","Ulcerative","Crohn Disease","RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2026-05-12",{"date":37,"type":22},"2029-01-29",{"name":39,"class":40},"Janssen Research & Development, LLC","INDUSTRY",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100643964","phase-1-a-study-to-assess-nipocalimab-concentrations-in-breast-milk-of-healthy-lactating-women-100643964","NCT07669077","A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Women","A Phase 1, Open-Label, Lactation Study to Assess Concentrations of Nipocalimab in Breast Milk of Healthy Lactating Women","Inclusion criteria:\n\n* Healthy on the basis of physical examination, medical history, vital signs, clinical laboratory tests, and 12-lead electrocardiogram (ECG) performed at screening\n* Study participant must have good venous accessibility in both arms\n* Study participant must be between 5 weeks and 24 months post-partum, inclusive, on Day -1\n* Study participant must agree, when nipple cream is needed during the assessment phase, to use only lanolin nipple cream\n* Study participant must have well established lactation and must be exclusively breast-feeding her infant (or not providing more than 1 supplemental bottle of formula\u002Fday) when enrolled in the study\n\nExclusion criteria:\n\n* Study participant has history of breast implants, breast augmentation, or breast reduction surgery\n* Study participant currently has active or unresolved mastitis at screening or Day -1\n* Study participant currently has or had an active clinically significant infection within the last 6 weeks\n* Study participant has any current or previous illness that, in the opinion of the investigator, might confound the results of the study or that could prevent, limit, or confound the protocol-specified assessments\n* Study participant has suspected or known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients",true,"FEMALE",{"count":52,"type":22},8,"INTERVENTIONAL",[55],"PHASE1","The main purpose of this study is to assess the concentrations of nipocalimab (pharmacokinetics \\[PK\\]) in the breast milk after administration of a single dose of nipocalimab into the vein, in healthy lactating women.",[58],"Healthy","NOT_YET_RECRUITING","2026-06-22",{"date":62,"type":33},"2026-06-25",{"date":64,"type":22},"2026-06-26",{"date":66,"type":22},"2027-02-16",{"name":39,"class":40},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":53,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100575146","phase-1-a-study-of-jnj-79635322-in-combination-with-daratumumab-with-or-without-lenalidomide-or-in-combination-with-pomalidomide-for-multiple-myeloma-100575146","NCT06768489","A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma","A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma","Inclusion Criteria:\n\n* Have documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria\n* Meet treatment regimen-specific requirements as follows: Treatment regimen A (JNJ-79635322+daratumumab):Treatment regimens A1 and A3: Have been treated with 1 to 3 prior lines of therapy, including a proteasome inhibitor (PI) and an inhibitor, immunomodulatory drug (IMiD) therapy for the treatment of multiple myeloma (MM); Treatment regimens A2 and A4: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments; Treatment regimen B (JNJ-79635322+pomalidomide): Have received greater than or equal to (\\>=) 1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory OR \\>=2 prior lines of therapy, including a PI and lenalidomide; Treatment Regimens C, D, and E: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments\n* Have a weight \\>=40 kilograms\n* Must have an Eastern Cooperative Oncology Group status of 0 or 2\n* Have measurable disease at screening as defined by at least 1 of the following: a) Serum monoclonal protein (M-protein) level \\>= 0.5 gram per deciliter (g\u002FdL); or b) Urine M-protein level \\>=200 milligram (mg)\u002F24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) \\>= 10 mg\u002FdL and abnormal serum Ig kappa lambda FLC ratio. d) For participants without measurable disease in the serum, urine, or involved FLC: presence of 1 or more focus of extramedullary disease which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion \\>=2 centimeter (cm) (at its greatest dimension) diameter on whole body positron emission tomography-computed tomography (or whole-body magnetic resonance imaging approved by sponsor), and not previously radiated\n\nExclusion Criteria:\n\n* Any serious underlying medical conditions, such as: a) Evidence of active viral, bacterial, or systemic fungal infection requiring ongoing antiviral, antibacterial, or antifungal treatment. b) Active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment. c) Cardiac conditions (myocardial infarction, unstable angina, or coronary artery bypass graft \\\u003C=6 months prior to enrollment; New York heart association stage III or IV congestive heart failure et cetera)\n* Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: a) Targeted therapy, epigenetic therapy, monoclonal antibody (mAb) treatment, or treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less. b) Gene-modified adoptive cell therapy (example, chimeric antigen receptor \\[CAR\\] modified T cells, natural killer cells) within 90 days. c) Prior anti-CD38 directed therapy within 90 days (for treatment regimens A, C, D and E only; within 21 days for treatment regimen B). d) Conventional chemotherapy within 21 days. e) PI therapy within 14 days. f) Immunomodulatory agent therapy within 7 days. g) Radiotherapy within 14 days\n* Stem cell transplantation: a) Allogeneic stem cell transplant within 6 months before the first dose of study treatment. b) Received an autologous stem cell transplant less than or equal to (\\\u003C=)12 weeks before the first dose of study treatment\n* Nonhematologic toxicity from prior anticancer therapy that has not resolved to baseline level or to grade \\\u003C=1 (except alopecia, tissue post-RT fibrosis \\[any grade\\] or peripheral neuropathy grade \\\u003C=3)\n* Prior treatment with CD3-redirecting therapy\n* The following medical conditions: pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation, human immunodeficiency (HIV) infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment",{"count":76,"type":22},140,[55],"The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \\[RP2Ds\\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).",[80],"Multiple Myeloma","2026-06-19",{"date":83,"type":33},"2026-06-24",{"date":85,"type":33},"2024-12-04",{"date":87,"type":22},"2029-01-02",{"name":39,"class":40},14,{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":53,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100567064","phase-1-a-study-of-jnj-89402638-for-metastatic-colorectal-and-gastric-cancers-100567064","NCT06663319","A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers","A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies","Inclusion Criteria:\n\n* For Part 1 (dose escalation), Part 2 (Arm A \\[JNJ-89402638 monotherapy\\]): Have histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma (CRC) progressing after 2 or more prior lines of standard therapy in the metastatic\u002Funresectable setting; For Part 2 Arm B (JNJ-89402638 + bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of CRC progressing after 2 or more prior lines of standard therapy in the metastatic\u002Funresectable setting; For Part 2 Arm C (JNJ-89402638 + FOLFOX\u002Fbevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of microsatellite stable (MSS) or proficient mismatch repair (pMMR) CRC progressing after 1 or more prior lines of standard therapy in the metastatic\u002Funresectable setting. Participants must have previously received a fluoropyrimidine and irinotecan doublet (such as FOLFIRI); For Part 2 Arm D (JNJ-89402638 + FOLFIRI\u002Fbevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of MSS or pMMR CRC progressing after 1 prior line of standard therapy in the metastatic\u002Funresectable setting. Must not have received irinotecan previously for metastatic disease; For Part 2 Arm E (JNJ-89402638 monotherapy in mGAC): Have histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma progressing after 1 or more prior lines of standard therapy in the metastatic\u002Funresectable setting\n* Have evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) version 1.1\n\n  1. Part 1: Must have either measurable or evaluable disease\n  2. Part 2: Must have at least 1 measurable lesion\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Have an estimated or measured glomerular filtration rate (GFR) greater than or equal to (\\>=) 30 milliliter per minute (mL\u002Fmin) based on modification of diet in renal disease (MDRD) 4-variable formula\n\nExclusion Criteria:\n\n* Active (new or progressive) brain metastases, leptomeningeal disease, or untreated spinal cord compression\n* Toxicity from prior anticancer therapy that has not resolved to Grade less than or equal to (\\\u003C=)1 (except alopecia, vitiligo, Grade \\\u003C= 2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement). For Part 2 Arm C: Grade 2 or higher peripheral neuropathy is considered exclusionary\n* Has a prior or concurrent second malignancy (other than the disease under study) unless natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment\n* Received glucocorticoids (doses \\>10 mg\u002Fday prednisone or equivalent) within 7 days prior to the first dose of study drug\n* Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment or within 4 weeks after the last dose of study treatment",{"count":98,"type":22},260,[55],"The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.",[102,103],"Colorectal Neoplasms","Gastrointestinal Neoplasms",{"date":83,"type":33},{"date":106,"type":33},"2024-10-15",{"date":108,"type":22},"2028-07-19",{"name":39,"class":40},11,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":53,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100644114","phase-3-a-study-of-ramantamig-plus-daratumumab-versus-daratumumab-bortezomib-lenalidomide-and-dexamethasone-dvrd-or-daratumumab-lenalidomide-and-dexamethasone-drd-in-participants-with-ndmm-for-whom-stem-cell-transplant-is-not-planned-100644114","NCT07665450","A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned","A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator's Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy","TRIlogy-7","Inclusion criteria:\n\n* Documented diagnosis of multiple myeloma (MM) according to the IMWG diagnostic criteria\n* Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to: i. ineligible due to advanced age; or ii. ineligible due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT; or iii. deferral of high-dose chemotherapy with ASCT as initial treatment\n* Have an eastern cooperative oncology status (ECOG) performance status of 0 to 2\n* Must sign an informed consent form (ICF)\n* Measurable disease at screening as assessed by central laboratory as defined in the protocol\n\nExclusion criteria:\n\n* Myeloma Frailty Score of greater than or equal to (\\>=) 2 with the exception of participants who have a score of 2 based on age alone\n* Suspected or known allergies, hypersensitivity, intolerance or other contraindications to any trial intervention or its excipients\n* Had major surgery (for example, requiring general anesthesia) or had significant traumatic injury within 2 weeks prior to first dose or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the trial\n* Known active or prior CNS involvement or exhibits clinical signs of meningeal involvement of MM\n* Received any prior therapy(ies) for treatment of MM or smoldering myeloma, with the exception of emergency use of a short course of corticosteroids",{"count":120,"type":22},1000,[122],"PHASE3","The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative complete response (CR) rate (percentage of participants in whom cancer cells are not detected) in participants with newly diagnosed multiple myeloma (NDMM; an initial stage of blood cancer that forms in a type of white blood cells \\[WBCs\\] called plasma cells) for whom stem cell transplant is not planned as initial therapy.",[80],"2026-06-18",{"date":83,"type":33},{"date":128,"type":22},"2026-09-14",{"date":130,"type":22},"2035-02-02",{"name":39,"class":40},{"id":133,"slug":134,"hasResults":12,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":50,"minAge":19,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":53,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":41},"100642162","phase-4-a-study-to-assess-concentration-of-tremfya-in-breast-milk-of-lactating-women-who-are-receiving-tremfya-therapeutically-100642162","NCT07654751","A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically","CNTO1959ISD4001: A Phase 4, Open-Label, Milk-Only Lactation Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically","Inclusion criteria:\n\n* Has an active diagnosis of at least one approved indication for guselkumab (psoriasis, psoriatic arthritis \\[PsA\\], UC and CD) as confirmed by medical records\n* Be medically stable on the basis of medical history review performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and initialed by the investigator\n* Currently is on established guselkumab maintenance therapy, that is, has received at least 2 guselkumab subcutaneous (SC) maintenance doses before Day 1\n* Has made the decision to be treated with guselkumab and to breastfeed independently prior to the participant consenting to participate in this study\n* Must be at least 5 weeks postpartum on Day 1\n* Have well-established lactation; participant must be exclusively breastfeeding their infant(s) (or not providing more than 1 supplemental bottle of formula\u002Fday) when enrolled in the study\n* Must plan to continue breastfeeding throughout the duration of the study\n\nExclusion criteria\n\n* Has any current or previous illness that, in the opinion of the investigator, might confound the results of the study or that could prevent, limit, or confound the protocol specified assessments\n* Has history of drug or alcohol abuse according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria within 1 year before screening\n* Uses or has used an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 1 month before enrolling in the study\n* Has received or plans to receive any live, attenuated vaccine within 12 weeks prior to administration of guselkumab. Non-live vaccines approved or authorized for emergency use (for example, Coronavirus disease-19 \\[COVID-19\\]) by local health authorities are allowed\n* Has a positive urine pregnancy test on Day 1",{"count":140,"type":22},10,[142],"PHASE4","The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.",[145,146,28,147],"Psoriasis","Colitis, Ulcerative","Arthritis, Psoriatic","2026-06-12",{"date":150,"type":33},"2026-06-17",{"date":152,"type":22},"2026-06-15",{"date":154,"type":22},"2027-08-31",{"name":39,"class":40},{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},"100641889","a-study-of-persistence-to-guselkumab-treatment-in-participants-with-moderate-to-severe-plaque-psoriasis-in-romania-100641889","NCT07582783","A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania","Persistence to Treatment With Guselkumab in Bio-Naive Patients With Moderate-to-Severe Plaque Psoriasis: A Romanian Non-Interventional Multi-center Observational Study","PROGRESS-RO","Inclusion criteria:\n\n* Has a confirmed diagnosis of moderate-to-severe plaque psoriasis\n* Participant must sign an informed consent form allowing source data verification in accordance with local requirements\n* Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments\n* No previous exposure to biological treatment, including guselkumab (bio-naive patient)\n* Intended for the treatment with guselkumab according to the approved indication\n\nExclusion criteria:\n\n* Meets any of the contraindications according to the latest version of the locally approved summary of product characteristics (SmPC)\n* Is pregnant or lactating\n* Current or recent (in the last 30 days prior to first SC dose of guselkumab) participation in any interventional study with investigational product.\n* Currently enrolled in another observational study sponsored or managed by a Johnson \\& Johnson company",{"count":165,"type":22},200,"This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.",[145],"2026-06-10",{"date":148,"type":33},{"date":171,"type":33},"2026-05-15",{"date":173,"type":22},"2028-11-10",{"name":39,"class":40},6,{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":18,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":53,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},"100567065","phase-3-a-long-term-extension-lte-study-of-guselkumab-in-pediatric-participants-100567065","NCT06663332","A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants","CNTO1959ISD3001: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis","TRILOGY","Inclusion Criteria:\n\n* Must have completed the dosing planned in the primary pediatric guselkumab study\n* Must have received benefit from continued guselkumab therapy in the opinion of the investigator\n* Before enrollment, a participant must be either: (a) Not of childbearing potential, OR (b) Of childbearing potential and not sexually active, practicing abstinence or a highly effective method of contraception and agrees to remain on a highly effective method while receiving study intervention and until 12 weeks after the last dose - the end of relevant systemic exposure\n* Parent(s) (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study. Assent is required from participants who are capable of understanding the nature of the study, typically those aged 7 years and older, to ensure their willingness to participate. An adolescent who provides assent will have the opportunity to sign an adult ICF upon reaching the age of majority, thereby affirming their understanding of the study's purpose and procedures, as well as their willingness to participate.\n\nExclusion Criteria:\n\n* Participant is greater than or equal to (\\>=) 18 years of age and resides in a country where 2 years have elapsed post marketing authorization for the respective adult indication\n* Participant is \\\u003C18 years of age and resides in a county where 2 years have elapsed post marketing authorization for the respective pediatric indication\n* Are pregnant, nursing, or planning pregnancy or fathering a child\n* Have taken any disallowed therapies before the planned first long-term extension (LTE) dose of study intervention\n* Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator\n* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments","3 Years",{"count":186,"type":22},196,[122],"The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).",[190,146,147,191],"Crohns Disease","Arthritis, Juvenile","2026-06-09",{"date":194,"type":33},"2026-06-11",{"date":196,"type":33},"2024-10-29",{"date":198,"type":22},"2032-02-25",{"name":39,"class":40},47,{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":53,"phases":211,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":4},"100642847","phase-2-a-study-evaluating-the-prophylactic-use-of-tocilizumab-to-prevent-cytokine-release-syndrome-with-ramantamig-administration-in-participants-with-relapsedrefractory-multiple-myeloma-100642847","NCT07589634","A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed\u002FRefractory Multiple Myeloma","79635322MMY2002: Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed\u002FRefractory Multiple Myeloma","TRI Pro","Inclusion criteria:\n\n* Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol\n* Received at least 1 prior lines of antimyeloma therapy\n* Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (\\>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response (that is, partial response or better) or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (\\\u003C=) 60 days after cessation of treatment\n* Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy\n* Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment\n\nExclusion criteria:\n\n* Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent\n* Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study\n* Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients\n* Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM that is considered at high risk of recurrence requiring systemic therapy\n* Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required",{"count":210,"type":22},230,[212],"PHASE2","The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.",[80],"2026-06-08",{"date":168,"type":33},{"date":218,"type":22},"2026-07-20",{"date":220,"type":22},"2030-11-08",{"name":39,"class":40},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":53,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},"100643826","phase-3-a-study-of-jnj-78934804-in-participants-with-moderately-to-severely-active-crohns-disease-100643826","NCT07577843","A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease","A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease","DUET ENCORE-CD","Inclusion criteria:\n\n* Have a diagnosis of Crohn's disease (CD) or fistulizing CD established greater than or equal to (\\>=) 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD\n* Have moderately to severely active CD based on crohn's disease activity index (CDAI) criteria defined as a baseline CDAI score \\>= 220 but less than or equal to (\\\u003C=) 450 and either: a. Mean daily stool frequency (SF) count \\>= 4.0, based on the unweighted CDAI component of the number of liquid or very soft stools or b. Mean daily AP score \\>= 2.0, based on the unweighted CDAI component of abdominal pain (AP)\n* Have moderately to severely active ileal and\u002For colonic CD as assessed by central review of the screening video ileocolonoscopy based on simple endoscopic score for crohn's disease (SES-CD) criteria\n* Have had an inadequate initial response, loss of response, or intolerance to previously approved systemic therapies\n\nExclusion criteria:\n\n* Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, ulcerative colitis (UC) or clinical findings highly suggestive of UC\n* Complications of CD such as symptomatic bowel strictures or stenoses, or any other manifestation that may require intestinal surgery while enrolled in the study\n* Presence of draining (that is, functioning) stoma or ostomy\n* Has a history of short bowel syndrome, is missing greater than (\\>) 2 of the 5 ileocolonic segments, or has any other medical condition that could preclude or confound the ability to use efficacy assessment tools (such as CDAI) to assess response to study intervention\n* Currently has or is suspected of having an abscess",{"count":231,"type":22},460,[122],"The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \\[worsens with time\\] and life-threatening disease of the intestine).",[28],"2026-06-04",{"date":215,"type":33},{"date":238,"type":33},"2026-05-22",{"date":240,"type":22},"2030-07-12",{"name":39,"class":40},5,{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":53,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100643295","phase-2-a-study-of-neoadjuvant-amivantamab-with-either-lazertinib-or-chemotherapy-in-participants-with-resectable-egfr-mutated-nsclc-100643295","NCT07586202","A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer","AmiNA","Inclusion Criteria:\n\n* Participant must have histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC) with completely resectable Stage II-IIIB N2 disease\n* Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a multidisciplinary team evaluation\n* Participant must consent to a screening biopsy, if clinically feasible, if no adequate tumor tissue is available for a baseline sample\n* Participant may have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s). Prior or concurrent second malignancies must be reviewed and agreed to with the medical monitor\n* Have an eastern cooperative oncology group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n* History of uncontrolled illness\n* Medical history of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis, or has current interstitial lung disease (ILD)\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening\n* Suspected or known allergies, hypersensitivity, or intolerance to excipients of: the combination of amivantamab and lazertinib or carboplatin and pemetrexed\n* Presence of primary driver mutations (anaplastic lymphoma kinase \\[ALK\\], mesenchymal-epithelial transition \\[MET\\], human epidermal growth factor receptor 2 \\[HER2\\], proto-oncogene tyrosine-protein kinase ROS \\[ROS1\\], neurotrophic tyrosine receptor kinase \\[NTRK\\], B-Raf proto-oncogene \\[BRAF\\], REarranged during transfection \\[RET\\], or kirsten rat sarcoma viral oncogene homolog \\[KRAS\\]) , besides EGFR Exon 19del or Exon 21 L858R mutations, as determined by local genomic testing\n* Prior treatment with any systemic anti-cancer therapy for NSCLC including EGFR-tyrosine kinase inhibitor (TKI) therapy, chemotherapy, biologic therapy, immunotherapy, or any investigational drug",{"count":252,"type":22},68,[212],"The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.",[256],"Carcinoma, Non-Small-Cell Lung",{"date":215,"type":33},{"date":259,"type":22},"2026-07-17",{"date":261,"type":22},"2028-04-01",{"name":39,"class":40},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":53,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":175},"100643529","phase-3-a-study-of-jnj-78934804-in-participants-with-moderately-to-severely-active-ulcerative-colitis-100643529","NCT07577856","A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis","A Phase 3 Randomized, Double-blind, and Active Controlled, Multi-center Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis","DUET ENCORE-UC","Inclusion criteria:\n\n* Diagnosis of ulcerative colitis (UC) established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of UC.\n* Moderately to severely active UC defined as baseline (Week 0) modified Mayo score of 5 to 9, inclusive, using the Mayo endoscopy subscore obtained during central review of the screening video endoscopy\n* An endoscopy subscore \\>=2 as obtained during central review of the screening video endoscopy\n* Have had an inadequate initial response, loss of response, or intolerance to previous approved systemic therapies\n\nExclusion criteria:\n\n* Isolated proctitis (UC limited to the rectum only or to less than \\[\\\u003C\\] 20 centimeter \\[cm\\] from the anal verge) as determined during central review of the screening video endoscopy OR Has a diagnosis of isolated proctitis\n* Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, Crohn's colitis or any findings suggestive of CD\n* Has a history of or ongoing chronic or recurrent infectious disease\n* Has previously demonstrated inadequate initial response, loss of response, allergy, hypersensitivity or intolerance to guselkumab or to golimumab\n* Is a participant who is pregnant, breastfeeding, or planning to become pregnant, or plans to father a child, while enrolled in this study or within 6 months after the last dose of study intervention",{"count":272,"type":22},644,[122],"The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).",[146],{"date":215,"type":33},{"date":278,"type":33},"2026-05-23",{"date":280,"type":22},"2030-10-30",{"name":39,"class":40},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":41},"100640477","a-real-world-study-of-ibrutinib-and-venetoclax-iv-first-line-treatment-given-for-fixed-duration-of-time-in-participants-with-chronic-lymphocytic-leukemia-100640477","NCT07602088","A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia","Prospective Cohort Study With Fixed-Duration Ibrutinib + Venetoclax (I+V) First-Line Treatment in Patients With Chronic Lymphocytic Leukemia in a Real-World Setting","REALITY-RO","Inclusion Criteria\n\n* Has a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) requiring treatment according to international workshop on chronic lymphocytic leukemia (iwCLL) 2018 guidelines\n* Intented for the treatment with fixed-duration ibrutinib plus venetoclax treatment (I+V) according to the approved indication. Decision to start I+V treatment must have been taken before and independently of participant's inclusion in the study\n* Participant must sign an informed consent form (ICF) allowing source data verification in accordance with local requirements\n* Is able to read, understand, and complete the PRO instruments in local language and comply with completion of all patient-reported outcome (PRO) instruments\n\nExclusion Criteria\n\n* Has a history of CLL\u002FSLL treatment\n* Has received an investigational medicinal product (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study or the first data collection time point\n* Is currently enrolled or plans to participate in an interventional clinical study (participation in a non-Janssen sponsored non-interventional study or registry is allowed)\n* Falls under any restrictions or limitations preventing treatment with I+V as per the current approved label of ibrutinib or venetoclax in Romania",{"count":291,"type":22},60,"The purpose of this study is to see how well Ibrutinib and Venetoclax (I+V) treatment works (effectiveness) for participants with chronic lymphocytic leukemia (CLL)\u002Fsmall lymphocytic lymphoma (SLL) when it is used in routine, everyday medical care.",[294],"Leukemia, Lymphocytic, Chronic, B-Cell",{"date":296,"type":33},"2026-06-05",{"date":298,"type":33},"2026-05-18",{"date":300,"type":22},"2029-11-30",{"name":39,"class":40},{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":53,"phases":311,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":321},"100636924","phase-1-a-study-of-jnj-95804306-for-relapsed-or-refractory-hematological-malignancies-100636924","NCT07572006","A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies","A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies","Inclusion criteria:\n\nFor Arm A:\n\n* Have a diagnosis of: Acute myeloid leukemia (AML) per International Consensus Classification (ICC) 2022 or myelodysplastic syndromes (MDS) per world health organization (WHO) 2022 classified as moderate high, high, or very high-risk per the molecular international prognostic scoring system (IPSSM). All participants must have relapsed or refractory disease and have exhausted or are ineligible for standard therapeutic options\n* Body weight greater than or equal to (\\>=) 40 kilograms (kg)\n* Eastern cooperative oncology group (ECOG) performance status of 0 to 2\n\nFor Arm B:\n\n* Have a diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\u002FSLL) that meets International workshop on chronic lymphocytic leukemia (iwCLL), National cancer institute (NCI) Working Group Guidelines which is relapsed or refractory and requires treatment with no other approved therapies available that would be more appropriate in the investigator's judgment. a. Participants must have received at least 2 prior lines of therapy; b. Participants who have received at least one prior line of therapy but are not eligible or do not have access to standard second line therapies, will be allowed to enroll\n* Body weight \\>= 40 kg\n* ECOG performance status of 0 to 2\n* Have clinically measurable disease\n* For US sites: Have a diagnosis of CLL\u002FSLL that meets iwCLL, NCI Working Group Guidelines which is relapsed or refractory and requires treatment with no other approved therapies available that would be more appropriate in the investigator's judgment. a. Participants must have received at least 2 prior lines of therapy\n\nExclusion criteria:\n\nFor Arm A:\n\n* Has acute promyelocytic leukemia according to world health organization (WHO) 2016 criteria or known active central nervous system (CNS) involvement of AML\u002FMDS, unless in specific cohort (s) per study evaluation team (SET) decision\n* Need for supplemental oxygen use to maintain adequate oxygenation\n* Have evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted\n* For US sites: Has acute promyelocytic leukemia according to WHO 2016 criteria or known active CNS involvement of AML\u002FMDS\n\nFor Arm B:\n\n* Need for supplemental oxygen use to maintain adequate oxygenation\n* Have evidence of uncontrolled systemic viral, bacterial, or fungal infection requiring initiation of parenteral treatment as medical intervention\n* Developed Richter's transformation or prolymphocytic leukemia\n* Known active CNS or leptomeningeal involvement of CLL\u002FSLL",{"count":310,"type":22},280,[55],"The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \\[RP2D\\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone and\u002For when administered in addition to standard of care (SoC) therapy at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system). For US sites: The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \\[RP2D\\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system).",[314],"Hematologic Neoplasms",{"date":296,"type":33},{"date":317,"type":33},"2026-05-13",{"date":319,"type":22},"2032-09-24",{"name":39,"class":40},3,{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":53,"phases":332,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":140},"100637014","phase-3-a-study-of-seltorexant-as-monotherapy-in-adults-and-elderly-participants-with-major-depressive-disorder-100637014","NCT07573176","A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder","A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With Seltorexant","Inclusion criteria:\n\n* Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features based upon clinical assessment\n* Experienced at least one MDD episode prior to their current episode\n* Current episode of MDD must be a minimum of 2 weeks in duration\n* Must meet one of the following criteria regarding current medication status.\n\n  1. Can be presenting for a new episode of MDD on no antidepressant treatment; however, must have been treated with an antidepressant medication in a prior episode for a minimum of 6 weeks at a stable dose at or above the minimum therapeutic level (medical record\u002Fsource document).\n\n     OR\n  2. Have taken up to two antidepressant treatments started in the current episode that were stopped (withdrawn), or will be withdrawn (washed out) due to inadequate response or intolerance.\n* Body Mass Index (BMI) between 18 and 40 kilograms per square meter (kg\u002Fm\\^2)\n* Must be medically stable on the basis of the following performed at screening and double-blind (DB) baseline: physical examination (including a brief neurological examination), vital signs (including blood pressure), and 12-lead electrocardiogram (ECG)\n\nExclusion criteria:\n\n* Use of ketamine\u002Fesketamine in the current depressive episode (up to 2 doses are allowed prior to screening)\n* Has treatment-resistant depression (TRD)\n* Has a primary DSM-5 diagnosis of panic disorder, generalized anxiety disorder, social anxiety disorder, or specific phobia which has been the primary focus of psychiatric treatment within the past 2 years\n* Current active DSM-5 diagnosis of obsessive-compulsive disorder, posttraumatic stress disorder, anorexia nervosa, bulimia nervosa, or fibromyalgia\n* Has a history or current diagnosis of a psychotic disorder, bipolar disorder, autism spectrum disorder, borderline personality disorder, or somatoform disorders\n* Has dementia, any dementing disease, intellectual disability, or neurocognitive disorder\n* Has a current or recent history of homicidal ideation or serious suicidal ideation within the past 3 months or a history of suicidal behavior within the past 6 months\n* Has a history of moderate-to-severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months\n* Has any significant sleep disorder, including but not limited to untreated\u002Funcontrolled conditions\n* Has known allergies, hypersensitivity, intolerance, or any contraindication to seltorexant or its excipients","74 Years",{"count":331,"type":22},600,[122],"The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder (\\[MDD\\], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and tolerability of JNJ-42847922 in participants with MDD in the open label treatment phase.",[335],"Depressive Disorder, Major",{"date":296,"type":33},{"date":338,"type":33},"2026-04-30",{"date":340,"type":22},"2029-05-03",{"name":39,"class":40},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":53,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":52},"100638107","phase-1-a-study-of-the-feasibility-safety-and-tolerability-of-aticaprant-as-adjunctive-treatment-in-participants-with-schizophrenia-100638107","NCT07615426","A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia","A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Phase 1b Study to Investigate the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia","KAPPTIVATE1001","Inclusion criteria:\n\n* Clinically stable with a diagnosis of schizophrenia confirmed by the mini international neuropsychiatric interview \\[MINI\\] for psychotic disorders\n* The participant must be on a stable dose of only one atypical antipyschotic medication\n* Must be receiving outpatient treatment for schizophrenia from a psychiatric provider at the time of screening\n* At the Baseline visit, must have a presence of permitted background antipsychotic medication based on blood samples drawn at the screening visit\n* If taking an antidepressant or anxiolytic, no dose changes are allowed to have occurred within 8 weeks prior to screening or throughout the double blind treatment phase\n\nExclusion criteria:\n\n* Has one or more of the current or prior (lifetime) diagnostic and statistical manual of mental disorders (5th edition) (DSM-5) diagnoses (based on the MINI for psychotic disorders): intellectual disability, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, psychotic disorder not otherwise specified (NOS), substance-induced psychotic disorder, bipolar disorder, major depressive disorder (recurrent or current episode)\n* Has a history of moderate-to-severe substance use disorder, including alcohol use disorder, according to DSM-5 criteria within 6 months before screening except for nicotine or caffeine (based on the MINI and clinical judgment)\n* Current cannabis (marijuana, pot, grass, hash, etcetera) use exceeds 3 to 5 times over the past 30 days as measured by items from the national survey on drug use and health (NSDUH) questionnaire\n* Has a history in the past 6 months of a peptic ulcer, or lifetime history of upper gastrointestinal bleeding, or known untreated helicobacter pylori infection, or has a diagnosis of zollinger-ellison syndrome (ZES)\n* Has current homicidal ideation\u002Fintent, per the investigator's clinical judgment","55 Years",{"count":352,"type":22},64,[55],"The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study\u002Fassessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.",[356],"Schizophrenia",{"date":296,"type":33},{"date":359,"type":33},"2026-03-02",{"date":361,"type":22},"2027-06-21",{"name":39,"class":40},{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":53,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":52},"100632784","phase-3-a-study-comparing-jnj-79635322-and-teclistamab-in-participants-with-relapsed-or-refractory-multiple-myeloma-100632784","NCT07518186","A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide","TRIlogy-5","Inclusion criteria:\n\n* Documented diagnosis of multiple myeloma (MM) as defined by the criteria below: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria, b. Measurable disease at screening as assessed by central laboratory\n* Received 1 to 3 prior lines of antimyeloma therapy, including an anti-cluster of differentiation (CD) 38 antibody and lenalidomide\n* Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication\n* Have clinical laboratory values meeting the criteria specified in the protocol during the screening and within 1 day of the start of administration of study treatment\n\nExclusion criteria:\n\n* Major surgery, (for example, requiring general anesthesia) or significant traumatic injury within 2 weeks prior to first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study\n* Suspected or known allergies, hypersensitivity, intolerance or other contraindications to the use of JNJ-79635322 or teclistamab or their excipients\n* Presence of any of the following: i. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); ii. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; iii. Any active malignancy (that is, progressing or requiring treatment change in the last 24 months) other than MM\n* Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required",{"count":372,"type":22},700,[122],"The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.",[80],{"date":296,"type":33},{"date":378,"type":33},"2026-05-31",{"date":380,"type":22},"2032-12-08",{"name":39,"class":40},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":53,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":401},"100631327","phase-3-a-study-of-guselkumab-versus-risankizumab-in-participants-with-moderately-to-severely-active-crohns-disease-100631327","NCT07499232","A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease","A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab Versus Risankizumab in the Treatment of Participants With Moderately to Severely Active Crohn's Disease","CHARGE","Inclusion criteria:\n\n* Has CD or fistulizing Crohn's Disease (CD) of at least 12 weeks' duration, with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, and\u002For endoscopy\n* Have moderately to severely active CD, defined as baseline Crohn's Disease Activity Index (CDAI) score greater than or equal to (\\>=) 220 but less than or equal to (\\\u003C=) 450\n* Baseline endoscopic evidence of active ileal and\u002For colonic CD as assessed by central endoscopy reading at the screening endoscopy defined as a screening Simple Endoscopic Score for Crohn's Disease (SES CD) \\>= 4 (for participants with isolated ileal disease) or \\>= 6 (for participants with colonic or ileocolonic disease), based on the presence of ulceration in any 1 of the 5 ileocolonic segments, resulting in the following specified ulceration component scores:\n\n  1. a minimum score of 1 for the component of \"size of ulcers\" AND\n  2. a minimum score of 1 for the component of \"ulcerated surface\"\n* In the opinion of the investigator, participant's disease is appropriate to treat with the maintenance dosing regimens utilized in the study\n* Adhere to the requirements for concomitant medications for the treatment of CD as mentioned in the protocol\n\nExclusion criteria\n\n* Has complications of CD such as symptomatic strictures or stenoses, short gut syndrome, active draining stoma or significant fistulizing disease or any other manifestation anticipated to require surgery within the next year, could preclude the use of the CDAI to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with guselkumab or risankizumab\n* Currently has or is suspected to have an abscess\n* Has an active fistula during screening or at Week 0 with an anticipated need for surgery\n* Has had any kind of bowel resection within 24 weeks, or any other intra-abdominal or other major surgery within 12 weeks, before first dose of study intervention\n* Currently has a malignancy or has a history of malignancy within 5 years before screening",{"count":391,"type":22},530,[122],"The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).",[28],{"date":296,"type":33},{"date":397,"type":33},"2026-04-21",{"date":399,"type":22},"2030-12-11",{"name":39,"class":40},30,{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":53,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":422},"100626658","phase-3-a-study-of-nipocalimab-in-adults-with-moderate-to-severe-systemic-lupus-erythematosus-100626658","NCT07438496","A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus","GARDENIA","Inclusion Criteria:-\n\n* Medically stable on the basis of physical examination, medical history, vital signs and 12-lead electrocardiogram (ECG) performed at screening\n* Clinical diagnosis of systemic lupus erythematosus (SLE) for more than or equal to (\\>=) 24 weeks prior to screening according to european league against rheumatism\u002Famerican college of rheumatology (EULAR\u002FACR) classification criteria\n* Must have a systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score \\>= 6 and a clinical SLEDAI-2K \\>= 4 at screening, AND a clinical SLEDAI-2K score \\>= 4 points at Week 0, excluding points attributed to \"lupus headache,\" \"alopecia,\" and \"organic brain syndrome\"\n* Participants of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-hCG) test at screening and a negative urine (β- hCG) test at Week 0 prior to randomization\n* Has at least 1 BILAG-2004 A score or 2 BILAG-2004 B scores observed at screening\n\nExclusion Criteria:\n\n* History of severe, progressive and\u002For uncontrolled hepatic, gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension, and\u002For any other medical or uncontrolled autoimmune disorder (s) or clinically significant abnormalities in screening laboratory\n* Any unstable or progressive manifestation of SLE that is likely to warrant escalation in therapy beyond permitted background medications\n* Confirmed or suspected clinical immunodeficiency syndrome not related to treatment of SLE or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant\n* Has shown a previous severe immediate hypersensitivity reaction, such as anaphylaxis, to therapeutic proteins\n* Suspected or known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients, or excipients used in the placebo formulation","75 Years",{"count":331,"type":22},[122],"The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs).",[415],"Lupus Erythematosus, Systemic",{"date":296,"type":33},{"date":418,"type":33},"2026-03-05",{"date":420,"type":22},"2031-11-07",{"name":39,"class":40},169,{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":53,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":242},"100617534","phase-1-a-study-of-pasritamig-jnj-78278343-in-combination-with-jnj-86974680-for-treatment-of-prostate-cancer-100617534","NCT07319871","A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer","A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer","Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the prostate. Primary small cell carcinoma, carcinoid tumor, neuroendocrine (NE) carcinoma, or large cell NE carcinoma arising in the prostate are not allowed; however, adenocarcinomas with NE features (for example \\[e.g.\\], immunohistochemistry \\[IHC\\] with both androgen receptor \\[AR\\]- and NE-marker positivity) are allowed\n* Metastatic castration-resistant prostate cancer (mCRPC) that is metastatic either to bone, any lymph node, or both without clear evidence of metastasis to visceral organs. Local-regional invasion (rectum, bladder) and bone disease with soft tissue component can be included\n* Prior orchiectomy or medical castration (for example, must be receiving ongoing androgen deprivation therapy with a gonadotropin-releasing hormone \\[GnRH\\] analog \\[agonist or antagonist\\] prior to the first dose of study drug and must continue this therapy throughout the treatment phase)\n* Prostate-specific antigen (PSA) greater than or equal to (\\>=) 2 nanograms per milliliters (ng\u002FmL) at screening\n* Measurable or evaluable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion criteria:\n\n* Toxicity related to prior anticancer therapy that has not returned to grade less than or equal to (\\\u003C=) 1 or baseline levels (except for alopecia, neuropathy \\[Grade 2\\] and vitiligo)\n* Known allergies, hypersensitivity, or intolerance to any of the components (for example, excipients) of pasritamig or JNJ-86974680\n* Active infection or condition that requires treatment with systemic antibiotics within 7 days prior to the first dose of study treatment. Antibiotic or antiviral prophylaxis is allowed\n* Have leptomeningeal disease or brain metastases, except participants with definitively, locally treated brain metastases that are clinically stable and asymptomatic \\>2 weeks, and who are off corticosteroid treatment for at least 2 weeks prior to first dose of study treatment\n* Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments",{"count":431,"type":22},40,[55],"The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.",[435],"Prostatic Neoplasms",{"date":296,"type":33},{"date":438,"type":33},"2026-01-14",{"date":440,"type":22},"2027-04-30",{"name":39,"class":40},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":53,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":461},"100616632","phase-1-a-study-of-jnj-95566692-in-participants-with-non-hodgkin-lymphoid-malignancies-100616632","NCT07308132","A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies","A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)","Inclusion Criteria:\n\n* B-cell non-Hodgkin lymphoid malignancies (NHL) according to World Health Organization (WHO) 2022 with relapsed or refractory disease and no other approved therapies available that would be more appropriate in the investigator's judgment. • Participants must have received at least 2 prior lines of therapy including an αCD20 monoclonal antibody containing chemotherapy combination schedule. • Participants who have received at least one prior line of therapy but are not eligible or do not have access to standard second line therapies, such as CAR-T, will be allowed to enroll\n* While on study treatment and for 3 months after the last dose of study treatment, a participant must: not breastfeed or become pregnant; not donate gametes (that is, eggs or sperm) or freeze for future use for the purposes of assisted reproduction; and wear an external condom\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Participants must have measurable disease as defined by the disease criteria (Lugano criteria)\n* Participants of childbearing potential must have a negative highly sensitive (for example, beta \\[β\\]-human chorionic gonadotropin) pregnancy test at screening and within 24 hours before the first dose of study treatment and agree to further pregnancy tests\n\nExclusion Criteria:\n\n* Known active central nervous system involvement (CNS) or leptomeningeal involvement\n* Prior solid-organ transplantation\n* Malignancy diagnosis other than the disease under study within 1 year prior to the first dose of the study treatment; exceptions are squamous and basal cell carcinoma of the skin, carcinoma in situ of the cervix and any malignancy that is considered cured or has minimal risk of recurrence within 1 year of first dose of the study treatment in the opinion of both the investigator and sponsor's medical monitor\n* Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (for example, methotrexate or tacrolimus) within 3 months prior to first dose of study treatment\n* Toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (\\\u003C=) 1 (except alopecia, vitiligo, peripheral neuropathy, or Grade \\\u003C=2 endocrinopathies that are stable on hormone replacement)",{"count":450,"type":22},130,[55],"The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) at the putative RP2D(s) (Part 2: Dose Expansion).",[454],"Lymphoma, Non-Hodgkin",{"date":296,"type":33},{"date":457,"type":33},"2026-01-20",{"date":459,"type":22},"2028-08-31",{"name":39,"class":40},9,{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":53,"phases":472,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":481},"100613426","phase-2-a-study-of-jnj-79635322-in-participants-with-relapsed-or-refractory-multiple-myeloma-100613426","NCT07266441","A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody","TRIlogy-3","Inclusion:\n\n* Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:\n\n  1. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria\n  2. Measurable disease at screening as assessed by central laboratory\n* Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD) 38 monoclonal antibody (mAb)\n* Documented evidence of progressive disease(PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by the IMWG criteria\n* Have discontinued concurrent use of any other anticancer treatment (including nonpalliative radiotherapy) or investigational agent\n* Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 to 2 at screening and immediately before the start of study treatment administration\n\nExclusion:\n\n* Suspected or known allergies, hypersensitivity, or intolerance to excipients of JNJ-79635322\n* Had major surgery within 2 weeks before first dose or has planned major surgery during study treatment phase\n* Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM\n* Participant has leptomeningeal disease\n* Participant has a prior or concurrent second malignancy the natural history or treatment of which could likely interfere with any study endpoints of safety or the efficacy of the study treatment",{"count":471,"type":22},157,[212],"The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.",[80],{"date":296,"type":33},{"date":477,"type":33},"2026-02-08",{"date":479,"type":22},"2028-12-12",{"name":39,"class":40},51,{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":53,"phases":492,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":252},"100617688","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-jnj-88545223-for-the-treatment-of-participants-with-active-psoriatic-arthritis-100617688","NCT07321873","A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis","A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 For the Treatment of Participants With Active Psoriatic Arthritis","VELOTA","Inclusion Criteria:\n\n* Have a diagnosis of psoriatic arthritis (PsA) for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening\n* Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (Week 0\u002FDay 1) based on the 66\u002F68 joint assessment; AND (b) C-reactive protein (CRP) greater than or equal to (\\>=) 0.1 milligrams per deciliter (mg\u002FdL) at screening from the central laboratory\n* Have \\>= 1 of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis\n* Have active plaque psoriasis with at least one psoriatic plaque of \\>= 2 centimeter (cm) diameter or nail changes consistent with psoriasis\n* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention\n\nExclusion Criteria:\n\n* Has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)\n* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (except PsA), psychiatric, genitourinary, or metabolic disturbances\n* Has suspected or known allergies, hypersensitivity, or intolerance to JNJ-88545223 or excipients used in the investigational medicinal product (IMP), including placebo (JNJ-88545223 investigator's brochure); or has a history of severe allergic reaction, angioedema, or anaphylaxis to drugs or food\n* Has fibromyalgia or osteoarthritis symptoms that, in the opinion of the investigator, would have potential to interfere with efficacy assessments\n* Currently has a malignancy or has a history of malignancy within 5 years prior to screening",{"count":491,"type":22},240,[212],"The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joint and skin health.",[147],{"date":296,"type":33},{"date":497,"type":33},"2026-01-15",{"date":499,"type":22},"2027-08-02",{"name":39,"class":40},{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":516,"leadSponsor":518,"locationsCount":41},"100616733","a-study-to-assess-real-world-use-and-outcomes-of-tar-200-for-participants-with-non-muscle-invasive-bladder-cancer-nmibc-in-the-united-states-100616733","NCT07309445","A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States","A Multicenter, Prospective, Longitudinal Study to Assess Real-World Use and Outcomes After the Launch of TAR-200 for NMIBC in the US","Nova-sTAR","Inclusion criteria:\n\n* Has a confirmed diagnosis of NMIBC based on TURBT or cold cup biopsy\n* Initiated first dose of TAR-200 in a real-world setting within 6 weeks prior to baseline visit\u002FStudy visit 1\n* Participants with childbearing potential are required to adhere to contraceptive recommendations as specified in the approved product labeling for TAR-200. Additionally, participants should seek consultation with their physician for personalized contraceptive advice\n* Must provide informed consent as described in the protocol\n\nExclusion criteria:\n\n* Has any medical condition deemed by the health care practitioner (HCP) as contraindicated to receive TAR-200 treatment\n* Had previous treatment with TAR-200 discontinued prior to baseline visit\u002FStudy visit 1\n* Previously received TAR-200 intravesically as part of a clinical trial(s)\n* Previously received greater than (\\>) 2 doses\u002Fcycles of TAR-200 in the real-world setting\n* Currently participating in an interventional bladder cancer clinical trial",{"count":510,"type":22},150,"The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).",[513],"Non-Muscle Invasive Bladder Neoplasms",{"date":296,"type":33},{"date":30,"type":22},{"date":517,"type":22},"2029-10-09",{"name":39,"class":40},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":53,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":41},"100615695","phase-1-a-study-of-14c-bleximenib-radiolabeled-in-participants-with-acute-leukemia-100615695","NCT07295951","A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia","An Open-Label Study to Investigate the Absorption, Metabolism, And Excretion (AME) Of 14C-Bleximenib (JNJ-75276617) in Participants With Acute Leukemia","Inclusion criteria:\n\n* Body weight greater than or equal to (\\>=) 40 kilograms (kg)\n* Relapsed or refractory (R\u002FR) acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 (NPM1), nucleoporin 98 (NUP98) or nucleoporin 214 (NUP214) gene alterations, and has exhausted, or is ineligible for available therapeutic options\n* Eastern cooperative oncology group (ECOG) performance status grade of 0 or 1\n* Regular bowel movements (that is \\[i.e.\\], average production of at least one stool every 2 days)\n* A woman of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment\n\nExclusion criteria:\n\n* Acute promyelocytic leukemia or diagnosis of Down syndrome associated leukemia, according to world health organization (WHO) 2016 criteria\n* Active central nervous system (CNS) disease\n* Recipient of solid organ transplant\n* Any toxicity (except for alopecia, stable peripheral neuropathy, thrombocytopenia, neutropenia, anemia) from previous anticancer therapy that has not resolved to baseline or to Grade 1 or less\n* Major surgery (e.g., requiring general anesthesia) within 2 weeks prior to first dose of study treatment or has not recovered from surgery or has major surgery planned during the time the participant is receiving study treatment",{"count":140,"type":22},[55],"The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).",[530,531,532],"Acute Lymphoblastic Leukemia","Acute Leukemias","Acute Myeloid Leukemia",{"date":296,"type":33},{"date":535,"type":33},"2025-11-18",{"date":537,"type":22},"2026-07-13",{"name":39,"class":40},""]